An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Muscle and Nerve

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mus.21350PMID 19760790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy

  2008cited by this paper
• The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study.

  2007cited by this paper
• Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number

  2006cited by this paper
• Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function

  2005cited by this paper
• Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2

  2004cited by this paper
• Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2

  2002cited by this paper
• Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

  2002cited by this paper
• A placebo-controlled trial of gabapentin in spinal muscular atrophy.

  2001cited by this paper
• The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy.

  2000cited by this paper
• Spinal muscular atrophy--clinical and genetic correlations.

  1997cited by this paper
• Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

  1997cited by this paper
• The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.

  1996cited by this paper
• THE STABILITY AND EQUIVALENCE RELIABILITY OF THE FUNCTIONAL INDEPENDENCE MEASURE FOR CHILDREN (WeeFIM)®

  1996cited by this paper

• An Exploratory 12-Month Observational Study of Adults with Spinal Muscular Atrophy: Learning from our Tools.

  2025cites this paper
• Assessing disease progression in spinal muscular atrophy, current gaps, and opportunities: a narrative review.

  2025cites this paper
• Quantitative synthetic MRI reveals grey matter abnormalities in patients with spinal muscular atrophy types 2 and 3

  2025cites this paper
• Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy

  2025cites this paper
• Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time

  2025cites this paper
• Evaluating Therapeutic Outcomes in Spinal Muscular Atrophy: An Indian Experience

  2025cites this paper
• Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice

  2024cites this paper
• The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review

  2024influential citation
• Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment

  2024cites this paper
• Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context

  2024cites this paper
• A Case Series Examining Clinic, Laboratory, and Physical Function After Administration of Nusinersen in Adults With Spinal Muscular Atrophy, a Single-Center Study

  2024cites this paper
• The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era

  2024cites this paper
• SMN2 Copy Number Association with Spinal Muscular Atrophy Severity: Insights from Colombian Patients

  2024cites this paper
• CRISPR-Cpf1 system and its applications in animal genome editing

  2024cites this paper
• Spinal muscular atrophy caused by compound heterozygous SMN1 mutations: two cases and literature review

  2024cites this paper
• Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era

  2023cites this paper
• Respiratory function in a large cohort of treatment-naïve adult spinal muscular atrophy patients: a cross-sectional study.

  2023cites this paper
• Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

  2023cites this paper
• A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients

  2023cites this paper
• Psychometric evaluation of modified spinal muscular atrophy functional rating scale (SMAFRS) in adult patients using Rasch analysis

  2023cites this paper
• Patient Reported Outcome Measures in Adult Spinal Muscular Atrophy: A Scoping Review and Graphical Visualization of the Evidence

  2022cites this paper
• Targeted-Deletion of a Tiny Sequence via Prime Editing to Restore SMN Expression

  2022cites this paper
• Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen

  2021cites this paper
• Generation of DMBi002-A human induced pluripotent stem cell line from patient with Spinal muscular atrophy type 3.

  2021cites this paper
• Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen

  2021cites this paper
• Update on Biomarkers in Spinal Muscular Atrophy

  2021cites this paper
• Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen

  2021cites this paper
• Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development

  2021cites this paper
• Neuromuscular disease and respiratory failure

  2021cites this paper
• Physical Therapy for Type III Spinal Muscular Atrophy in a Uyghur Pedigree

  2021cites this paper
• Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy

  2021cites this paper
• Nusinersen Treatment in Adults With Spinal Muscular Atrophy

  2021cites this paper
• Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy

  2021cites this paper
• Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

  2021cites this paper
• Motor Neuron Diseases

  2021cites this paper
• Report on the 5th Ottawa International Conference on Neuromuscular Disease & Biology –October 17-19, 2019, Ottawa, Canada

  2021cites this paper
• A novel CARM1-HuR axis involved in muscle differentiation and plasticity misregulated in spinal muscular atrophy.

  2021cites this paper
• The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment

  2020cites this paper
• Cerebellar degeneration in adult spinal muscular atrophy patients

  2020cites this paper
• Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review

  2020cites this paper
• Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen

  2020cites this paper
• Spinal Muscular Atrophy in the Treatment Era.

  2020cites this paper
• Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

  2019cites this paper
• Therapieevaluation bei Patienten mit 5q-assoziierter spinaler Muskelatrophie

  2019cites this paper
• Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy

  2019cites this paper
• Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells

  2018cites this paper
• The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study

  2018cites this paper
• A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen

  2018cites this paper
• Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?

  2018cites this paper
• Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates

  2018cites this paper
• Spinal muscular atrophy: Selective motor neuron loss and global defect in the assembly of ribonucleoproteins.

  2018cites this paper
• Cytoskeleton and molecular motors in the causation of motor neuron diseases

  2018cites this paper
• Increase of hyperpolarization‐activated cyclic nucleotide‐gated current in the aberrant excitability of spinal muscular atrophy

  2018cites this paper
• Decreased Motor Neuron Support by SMA Astrocytes due to Diminished MCP1 Secretion

  2017cites this paper
• Natural history of infantile‐onset spinal muscular atrophy

  2017cites this paper
• Mammalian Models of Spinal Muscular Atrophy

  2017cites this paper
• Natural History of Spinal Muscular Atrophy

  2017cites this paper
• Gender-Specific Amelioration of SMA Phenotype upon Disruption of a Deep Intronic Structure by an Oligonucleotide.

  2017cites this paper
• SECIS-binding protein 2 interacts with the SMN complex and the methylosome for selenoprotein mRNP assembly and translation

  2017cites this paper
• Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study

  2016cites this paper
• Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration

  2016cites this paper
• Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.

  2016cites this paper
• Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases

  2016cites this paper
• Effect of genetic background on the phenotype of the Smn2B/- mouse model of spinal muscular atrophy

  2016cites this paper
• SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR

  2015cites this paper
• Spinal Muscular Atrophy.

  2015cites this paper
• Spinal muscular atrophy—recent therapeutic advances for an old challenge

  2015cites this paper
• Spinal muscular atrophy: Diagnosis and management in a new therapeutic era

  2015cites this paper
• Chapter 89 – Spinal Muscular Atrophy

  2015cites this paper
• Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls

  2015cites this paper
• Transcriptome Profiling of Spinal Muscular Atrophy Motor Neurons Derived from Mouse Embryonic Stem Cells

  2014cites this paper
• An increase in copy number of Myosin Light Chain Kinase 1 associates with increased force production in Lithuanian athletes

  2014influential citation
• Systems Biology Investigation of cAMP Modulation to Increase SMN Levels for the Treatment of Spinal Muscular Atrophy

  2014cites this paper
• Forced oscillation technique in spinal muscular atrophy.

  2014cites this paper
• Spinal Muscular Atrophies

  2014cites this paper
• Outcome Measures and Clinical Assessment Instruments in Neuromuscular Disease

  2014cites this paper
• SMA valiant trial: A prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy

  2014cites this paper
• Implication of the SMN complex in the biogenesis and steady state level of the Signal Recognition Particle

  2012cites this paper
• A practical approach to molecular diagnostic testing in neuromuscular diseases.

  2012cites this paper
• Newborn screening for spinal muscular atrophy by calibrated short-amplicon melt profiling.

  2012cites this paper
• Genotype-phenotype relationship in 2 SMA III patients with novel mutations in the Tudor domain

  2012cites this paper
• Corticomotoneuronal integrity and adaptation in spinal muscular atrophy.

  2012cites this paper
• Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)

  2011cites this paper
• Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy

  2011cites this paper
• Stabilization of the survival motor neuron protein by ASK1

  2011cites this paper
• Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR.

  2011cites this paper
• Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA

  2011cites this paper
• A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2

  2010cites this paper
• Spinal muscular atrophy

  2000cites this paper